Home / Intelligence / Webinars / 2023 NRDL Update: An Ongoing Voyage of Innovation and Accessibility
Available On Demand
How can manufacturers strategize for pricing and market access success amidst the evolving landscape of China’s NRDL?
As China continues to be a key pharmaceutical market, understanding the latest National Reimbursement Drug List (NRDL) trends and policy evolvement is crucial for manufacturers aiming to achieve successful access and pricing outcomes.
In this webinar, a panel of Trinity Life Sciences’ Value, Access and Pricing experts will discuss the role of the new value-based assessment framework in NRDL payer decision-making and dive into the nuances of 2023 NRDL pricing outcomes to inform manufacturer strategies in navigating the dynamic access and pricing landscape in China.
Key Webinar Topics:
- Overview of the 2023 China NRDL update: changes, trends and outcomes
- Case studies of oncology and rare disease drugs: takeaways from success and failure stories
- Recommendation and outlook for future NRDL updates
Featuring
Max Hunt
Partner,
Evidence, Value, Access & Pricing
Wenting Zhang
Director,
Evidence, Value, Access & Pricing
Flora Chung
Engagement Manager,
Value, Access & Pricing
Rya Zhang
Consultant,
Value, Access & Pricing
Complete the form below to view the on-demand webinar.
By submitting this form, creating an account, and/or using our website (or using our Services) you agree to our Privacy Policy. Information provided by you is stored in our database and may be used for sending you additional information about Trinity (including Trinity’s partners and affiliates) and our products and services. Such information may be transferred for this purpose to Trinity and affiliates in other countries. If you would like to opt out in the future, please email _compliance@trinitylifesciences.com.
This webinar will be hosted within the ON24 platform, which requires the usage of Javascript and Cookies. Please see ON24’s Privacy Policy for more information.
Related Intelligence
Webinars
Part D in Peril: The Inconvenient Math of IRA Part D Redesign
August 14, 2025 | 12:00 – 12:45 PM ET
Medicare Part D is undergoing its most significant transformation in decades largely driven by the IRA. What does this mean for pharmaceutical manufacturers? Join us for an engaging discussion with Max Hunt, Partner at Trinity, and special guest Dan Simenc, clinical and actuarial expert at Milliman, as they provide perspectives on recent developments and future expectations for Medicare Part D and Medicare Advantage.
Sign Up Now
Blog
NRDL 2024: Rare Diseases Deep Dive
China’s pharmaceutical landscape is not only vast in scale but also rapidly evolving with an emphasis on balancing access with affordability. This year’s NRDL update stands out. The introduction of the value rating system continues to raise the bar for clinical innovation, rewarding innovation that truly addresses unmet needs and demonstrates clear differentiation. The National […]
Read More
Blog
Joint Clinical Assessment in the EU: What Life Sciences Companies Need to Know
March 2025 marked a pivotal moment for pharmaceutical and biotech companies operating in the European Union (EU) as the first two molecules began to proceed through the Joint Clinical Assessment (JCA) process. At a recent seminar hosted by Trinity Life Sciences, stakeholders gathered to explore the implications of this new regulatory framework and how to […]
Read More